Primary systemic therapy of ovarian cancer

被引：0

作者：

Pfisterer J. ^{[1
]}

Hilpert F. ^{[2
]}

Mahner S. ^{[3
]}

Harter P. ^{[4
]}

Du Bois A. ^{[4
]}

机构：

[1] Zentrum für Gynäkologische Onkologie Kiel, 24103 Kiel

[2] Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig Holstein Campus Kiel

[3] Klinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg

[4] Klinik für Gynäkologie und Gynäkologische Onkologie, Kliniken Essen Mitte, Essen

来源：

Der Gynäkologe | 2013年 / 46卷 / 8期

关键词：

Angiogenesis inhibition; Bevacizumab; Chemotherapy; Metastases; Targeted therapy;

D O I：

10.1007/s00129-012-3113-7

中图分类号：

学科分类号：

摘要：

Standard primary systemic treatment of patients with advanced ovarian cancer comprises six courses of intravenously administered carboplatin and paclitaxel. In patients with FIGO stage IIIB-IV disease, additional treatment with bevacizumab is possible. Primary, neoadjuvant treatment without prior debulking surgery should be avoided. Intraperitoneal treatments, including HIPEC, should only be given within controlled clinical trials. © 2013 Springer-Verlag Berlin Heidelberg.

引用

页码：541 / 546

页数：5

共 22 条

[1]

S3-Leitlinie Diagnostik, Therapie und Nachsorge Maligner Ovarialtumoren, (2013)

[2]

International Collaborative Ovarian Neoplasm Trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer, J Natl Cancer Inst, 95, pp. 125-132, (2003)

[3]

Trimbos J.B., Vergote I., Bolis G., Et al., Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial, J Natl Cancer Inst, 95, pp. 113-125, (2003)

[4]

Du Bois A., Luck H.J., Meier W., Et al., A randomized clinical trial of-cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J Natl Cancer Inst, 95, 17, pp. 1320-1329, (2003)

[5]

Ozols R.F., Bundy B.N., Greer B.E., Et al., Phase III trial of carboplatin and paclitaxel compared with-cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study, J Clin Oncol, 21, 17, pp. 3194-3200, (2003)

[6]

Lindemann K., Christensen R.D., Vergote I., Et al., First-line treatment of advanced ovarian cancer with paclitaxel/ carboplatin with or without epirubicin (TEC versus TC) - A gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG, Ann Oncol, 23, 10, pp. 2613-2619, (2012)

[7]

Du Bois A., Weber B., Rochon J., Et al., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, J Clin Oncol, 24, 7, pp. 1127-1135, (2006)

[8]

Pfisterer J., Weber B., Reuss A., Et al., Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO, J Natl Cancer Inst, 98, 15, pp. 1036-1045, (2006)

[9]

Hoskins P., Vergote I., Cervantes A., Et al., Advanced ovarian cancer: Phase III randomized study of sequential-cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel, J Natl Cancer Inst, 102, 20, pp. 1547-1556, (2010)

[10]

Du Bois A., Herrstedt J., Hardy-Bessard A.C., Et al., Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer, J Clin Oncol, 28, 27, pp. 4162-4169, (2010)

← 1 2 3 →